Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Neurology

Why is a Thymectomy Done for Myasthenia Gravis?

At a Glance

A thymectomy is done for myasthenia gravis to remove the thymus gland, which often mistakenly trains the immune system to attack muscle receptors. Removing it can significantly improve muscle strength, reduce reliance on steroids like prednisone, and sometimes lead to disease remission over time.

Your doctor is likely recommending a thymectomy—the surgical removal of the thymus gland—because it has been proven to improve long-term muscle strength and significantly reduce the need for heavy immune-suppressing medications [1][2]. In many people with myasthenia gravis (MG), the thymus gland acts as a faulty training center that teaches the immune system to attack the body’s own muscles [3][4]. Removing this gland can calm the immune system down, leading to fewer symptoms, less reliance on steroids like prednisone, and in some cases, eventually leading to a complete remission of the disease [5][6].

The Thymus Gland’s Role in MG

Normally, the thymus is a small gland located in the upper chest that helps develop your immune system during childhood by training T-cells (a type of white blood cell) to fight infections while leaving your own tissues alone [7]. However, in people with MG, the thymus often remains unusually active and becomes inflamed [3]. It develops abnormal clusters of immune cells that mistakenly learn to produce antibodies against the acetylcholine receptors (AChR)—the crucial docking stations on your muscles that receive nerve signals [4][8]. By removing the thymus, you are essentially shutting down the headquarters of this rogue immune response.

Proven Benefits: The MGTX Trial

For many years, doctors believed thymectomy helped MG patients, but a landmark international study called the MGTX trial provided undeniable proof [1]. The trial compared patients taking prednisone alone to those who took prednisone and had a thymectomy. The results were clear:

  • Improved Muscle Strength: Patients who had surgery showed significantly better, more stable muscle strength over three to five years [1][2].
  • Lower Steroid Doses: The surgery group needed significantly less prednisone to control their symptoms, dropping their average required dose by about 50% at the five-year mark [5][2].
  • Fewer Side Effects: Because they took fewer immune-suppressing drugs, the surgery group experienced fewer treatment-related side effects and reported lower levels of distress [1].

A Gradual Process: Setting Expectations

It is crucial to understand that a thymectomy is not an overnight fix. Because it takes time for your immune system to “reset” and for the circulating rogue antibodies to clear from your bloodstream, the benefits of the surgery are usually delayed [1]. Most patients do not experience symptom relief or reductions in medication immediately after waking up from surgery. Instead, improvement is a gradual process that often takes many months or even 1 to 2 years to fully manifest.

Who Benefits the Most?

Research shows that thymectomy is highly effective for people with generalized MG who test positive for AChR antibodies (the most common type of MG antibody) [9][10]. It is especially recommended as an early intervention for “early-onset” MG, typically meaning patients under the age of 65 who have had symptoms for fewer than five years [2][10]. Operating earlier in the course of the disease generally leads to more favorable clinical outcomes [11][6].

However, it is not for everyone. Thymectomy is generally not recommended or considered beneficial for patients with a different antibody profile, such as those with MuSK-positive myasthenia gravis, unless a tumor is present [9].

Dealing with Thymomas

In about 10-15% of people with MG, a tumor called a thymoma grows on the thymus gland. While these tumors are usually slow-growing, they do have the potential to spread or become malignant (cancerous) [12][13]. Your doctor will typically order a CT scan or MRI of your chest to check for this [14]. If your scan shows a thymoma, surgically removing it is considered the absolute standard of care, regardless of how mild or severe your MG symptoms are, and regardless of your specific antibody status [14][15].

What About the Surgery Itself?

It is completely normal to feel intimidated by the idea of chest surgery. However, thoracic (chest) surgery has advanced remarkably. While open-chest surgery (which requires splitting the breastbone) was once the standard, many surgeons now use minimally invasive or robotic-assisted techniques [14][16].

These modern approaches use very small incisions on the side of the chest. For patients, this generally translates to a much shorter hospital stay (often just 1 to 3 days instead of a week or more), significantly less postoperative pain, smaller scars, and a return to normal activities in a matter of weeks rather than months [14][17].

While minimally invasive methods are safer and easier on the body, it is important to remember that thymectomy is still a major surgery. All surgeries carry risks, such as bleeding, infection, or potential injury to nearby structures like the phrenic nerve (which controls the diaphragm) [18]. You should have a thorough discussion with your thoracic surgeon about what the actual surgical pain, scarring, and specific risks will look like for you.

Common questions in this guide

What happens to myasthenia gravis symptoms after a thymectomy?
Improvement in symptoms is a gradual process that usually takes months or even one to two years. Over time, many patients experience better, more stable muscle strength and a significantly reduced reliance on heavy immune-suppressing medications.
Who is the best candidate for a thymectomy?
You are likely a strong candidate if you have early-onset, generalized myasthenia gravis, are under age 65, and test positive for AChR antibodies. It is also required for any patient who has a thymoma tumor on their thymus gland.
Do I still need surgery if my myasthenia gravis symptoms are mild?
If a scan reveals a thymoma tumor, surgical removal is the standard of care regardless of how mild your symptoms are. For patients without a tumor, operating early in the course of the disease generally leads to more favorable clinical outcomes.
How is a thymectomy procedure performed?
While traditional open-chest surgery was once the standard, many surgeons now use minimally invasive or robotic-assisted techniques. These modern approaches use very small incisions, resulting in shorter hospital stays, less pain, and faster recovery.
Are there risks associated with thymus removal surgery?
Like all major surgeries, a thymectomy carries risks such as bleeding and infection. There is also a specific risk of injury to nearby structures like the phrenic nerve, which controls your diaphragm.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I a candidate for a minimally invasive or robotic thymectomy, or does my specific anatomy require an open approach?
  2. 2.Have you reviewed my recent chest CT scan, and is there any evidence of a thymoma or thymic hyperplasia?
  3. 3.Given my specific antibody status and age, what is the statistical likelihood that this surgery will allow me to lower my daily prednisone dose?
  4. 4.What are the specific risks of this surgery for me, particularly regarding potential damage to the phrenic nerve?
  5. 5.How many robotic or minimally invasive thymectomies for myasthenia gravis do you perform in a typical year?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Randomized Trial of Thymectomy in Myasthenia Gravis.

    Wolfe GI, Kaminski HJ, Aban IB, et al.

    The New England journal of medicine 2016; (375(6)):511-22 doi:10.1056/NEJMoa1602489.

    PMID: 27509100
  2. 2

    Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.

    Wolfe GI, Kaminski HJ, Aban IB, et al.

    The Lancet. Neurology 2019; (18(3)):259-268 doi:10.1016/S1474-4422(18)30392-2.

    PMID: 30692052
  3. 3

    Clinical Genomic, phenotype and epigenetic insights into the pathology, autoimmunity and weight management of patients with Myasthenia Gravis (Review).

    Golfinopoulou R, Papageorgiou L, Efthimiadou A, et al.

    Molecular medicine reports 2021; (24(1)).

    PMID: 34225443
  4. 4

    Il-23/Th17 cell pathway: A promising target to alleviate thymic inflammation maintenance in myasthenia gravis.

    Villegas JA, Bayer AC, Ider K, et al.

    Journal of autoimmunity 2019; (98()):59-73 doi:10.1016/j.jaut.2018.11.005.

    PMID: 30578016
  5. 5

    Randomized Trial of Thymectomy in Myasthenia Gravis.

    Wolfe GI, Kaminski HJ, Cutter GR

    The New England journal of medicine 2016; (375(20)):2006-2007 doi:10.1056/NEJMc1611704.

    PMID: 27959593
  6. 6

    Thymoma negatively affects the neurological outcome of myasthenia gravis after thymectomy: a propensity score matching study.

    Tian W, Yu H, Sun Y, et al.

    Journal of cardiothoracic surgery 2024; (19(1)):37 doi:10.1186/s13019-024-02511-6.

    PMID: 38297367
  7. 7

    Thymus and autoimmunity.

    Marx A, Yamada Y, Simon-Keller K, et al.

    Seminars in immunopathology 2021; (43(1)):45-64 doi:10.1007/s00281-021-00842-3.

    PMID: 33537838
  8. 8

    Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis.

    Jiang R, Hoehn KB, Lee CS, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2020; (117(48)):30649-30660 doi:10.1073/pnas.2007206117.

    PMID: 33199596
  9. 9

    Point Counter-Point: Thymectomy in Ocular Myasthenia Gravis.

    Vickers A, Adesina OO, Lee AG, Van Stavern GP

    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2022; (42(4)):541-546 doi:10.1097/WNO.0000000000001748.

    PMID: 36394968
  10. 10

    Thymectomy in myasthenia gravis.

    Rath J, Moser B, Zimprich F

    Current opinion in neurology 2023; (36(5)):416-423 doi:10.1097/WCO.0000000000001189.

    PMID: 37639450
  11. 11

    Pre-thymectomy disease severity predicts outcome in acetylcholine receptor antibody-positive generalised myasthenia gravis.

    Papathanasiou A, Tench CR, Ambrose PA, et al.

    Journal of neurology 2024; (271(9)):6220-6226 doi:10.1007/s00415-024-12592-x.

    PMID: 39080053
  12. 12

    Pathological Features and Prognosis of Thymoma With or Without Myasthenia Gravis.

    Zhang Y, Yu L, Ke J

    Frontiers in surgery 2022; (9()):726673 doi:10.3389/fsurg.2022.726673.

    PMID: 35252321
  13. 13

    Primary thymus tumors: retrospective case analysis at a reference center in Latin America, 2011-2019.

    Scarpetta-Gonzalez DF, Morales EI, Sua LF, et al.

    BMC cancer 2021; (21(1)):279 doi:10.1186/s12885-021-07920-7.

    PMID: 33726691
  14. 14

    Robotic thymectomy for thymoma in patients with myasthenia gravis: neurological and oncological outcomes.

    Romano G, Zirafa CC, Ceccarelli I, et al.

    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2021; (60(4)):890-895 doi:10.1093/ejcts/ezab253.

    PMID: 34263301
  15. 15

    A case of thymoma in myasthenia gravis: Successful outcome after thymectomy.

    Dahal S, Bhandari N, Dhakal P, et al.

    International journal of surgery case reports 2019; (65()):229-232 doi:10.1016/j.ijscr.2019.10.069.

    PMID: 31734473
  16. 16

    Clinical study of thoracoscopic assisted different surgical approaches for early thymoma: a meta-analysis.

    Wang J, Tong T, Zhang K, et al.

    BMC cancer 2024; (24(1)):92 doi:10.1186/s12885-024-11832-7.

    PMID: 38233754
  17. 17

    Minimally Invasive versus Open Thymectomy for Thymic Malignancies: Systematic Review and Meta-Analysis.

    Friedant AJ, Handorf EA, Su S, Scott WJ

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016; (11(1)):30-8.

    PMID: 26762737
  18. 18

    Efgartigimod is a new option for the treatment of thymoma associated myasthenia gravis: A case report.

    Wang S, Wang Q, Jin L, et al.

    International journal of surgery case reports 2024; (115()):109241 doi:10.1016/j.ijscr.2024.109241.

    PMID: 38219512

This page is for informational purposes only and does not replace professional medical advice. Always consult your neurologist and thoracic surgeon regarding your specific myasthenia gravis treatment options and surgical risks.

Get notified when new evidence is published on Myasthenia gravis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.